One 80 mg vial contains GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, and KPV 10 mg a copper-remodeling anchor plus three recovery/anti-inflammatory peptides
Clinical Evidence in Humans The topical evidence base is unusually robust for a research peptide: Facial aging study (71 women, 12 weeks): A GHK-Cu facial cream documented increased skin density and thickness, reduced laxity, improved clarity, and reduced fine lines and depth of wrinkles (PMID 26236730)
The April 2026 FDA action removes them from the Category 2 restricted compounding list effective April 23, 2026, and the FDAs Pharmacy Compounding Advisory Committee will review their compounding eligibility under 503A at its July 23-24, 2026 meeting
[PubMed] [Google Scholar] 34.Thimmulappa RK, Lee H, Rangasamy T, et al